Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections

Objective: To assess the occurrence of anticardiolipin antibodies (ACA) (as well as of anti-DNA antibodies) in patients with rheumatoid arthritis treated with etanercept or combination therapy. Methods: Eight patients treated with etanercept 25 mg twice weekly were studied for a period of 85 weeks....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2002-04, Vol.61 (4), p.358-361
Hauptverfasser:	Ferraccioli, G, Mecchia, F, Di Poi, E, Fabris, M
Format:	Artikel
Sprache:	eng
Schlagworte:	ACA Adolescent Adult Aged ANA Antibiotics Antibodies, Anticardiolipin - analysis Antibodies, Antinuclear - analysis Anticardiolipin antibodies antinuclear antibodies Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents C reactive protein Child Child, Preschool Chloroquine - therapeutic use Colonies & territories Concise Report CRP CsA cyclosporin A Cyclosporine - therapeutic use Deoxyribonucleic acid disease modifying antirheumatic drugs DMARDs DNA Drug Combinations Drug therapy E coli Etanercept Fever Humans Immunoglobulin G - analysis Immunoglobulin G - therapeutic use Immunoglobulin M - analysis Immunoglobulins Immunology Infant Infant, Newborn Infections Laboratories Medical sciences methotrexate Methotrexate - therapeutic use Middle Aged MTX Pharmacology. Drug treatments Physiological aspects Receptors, Tumor Necrosis Factor - therapeutic use Rheumatoid arthritis Software Staphylococcal Infections - drug therapy Staphylococcal Infections - immunology staphylococcus Staphylococcus aureus TNFα tumour necrosis factor α
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!